Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes?

Judith Aron-Wisnewsky, Karine Clément, Max Nieuwdorp

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Purpose of Review: The aim of this review is to summarize the current data available on the metabolic effects of fecal microbiota transplantation (FMT) including obesity and glucose metabolism in humans. Recent Findings: Gut microbiota dysbiosis is a frequent characteristic observed in obesity and related metabolic diseases. Pieces of evidence mostly generated in mouse models suggest that rescuing this dysbiosis associates with improved metabolism. In humans, dietary or bariatric surgery interventions are often accompanied by complete or partial restoration of this dysbiosis together with weight reduction and metabolic amelioration. FMT is an interesting option to modify gut microbiota and has been associated with improved clinical outcomes, albeit only used in routine care for Clostridium difficile infection. However, there are only limited data on using FMT in the metabolic context. Summary: FMT from lean donors significantly improves insulin sensitivity in obese subjects with metabolic syndrome. However, there is a wide range of clinical responses. Interestingly in subjects with high microbial gene richness at baseline and when FMT donors that are metabolically compromised are used, no metabolic improvement is seen. Moreover, more studies evaluating the effect of FMT in patients with overt type 2 diabetes are warranted. Furthermore, interventions (in the receiver prior to FMT) aiming to enhance FMT response also need evaluation.
Original languageEnglish
Article number51
JournalCurrent Diabetes Reports
Volume19
Issue number8
DOIs
Publication statusPublished - 2019

Cite this

@article{cfa3030dd3184584abe3453e62ed17f1,
title = "Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes?",
abstract = "Purpose of Review: The aim of this review is to summarize the current data available on the metabolic effects of fecal microbiota transplantation (FMT) including obesity and glucose metabolism in humans. Recent Findings: Gut microbiota dysbiosis is a frequent characteristic observed in obesity and related metabolic diseases. Pieces of evidence mostly generated in mouse models suggest that rescuing this dysbiosis associates with improved metabolism. In humans, dietary or bariatric surgery interventions are often accompanied by complete or partial restoration of this dysbiosis together with weight reduction and metabolic amelioration. FMT is an interesting option to modify gut microbiota and has been associated with improved clinical outcomes, albeit only used in routine care for Clostridium difficile infection. However, there are only limited data on using FMT in the metabolic context. Summary: FMT from lean donors significantly improves insulin sensitivity in obese subjects with metabolic syndrome. However, there is a wide range of clinical responses. Interestingly in subjects with high microbial gene richness at baseline and when FMT donors that are metabolically compromised are used, no metabolic improvement is seen. Moreover, more studies evaluating the effect of FMT in patients with overt type 2 diabetes are warranted. Furthermore, interventions (in the receiver prior to FMT) aiming to enhance FMT response also need evaluation.",
author = "Judith Aron-Wisnewsky and Karine Cl{\'e}ment and Max Nieuwdorp",
year = "2019",
doi = "10.1007/s11892-019-1180-z",
language = "English",
volume = "19",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "8",

}

Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes? / Aron-Wisnewsky, Judith; Clément, Karine; Nieuwdorp, Max.

In: Current Diabetes Reports, Vol. 19, No. 8, 51, 2019.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes?

AU - Aron-Wisnewsky, Judith

AU - Clément, Karine

AU - Nieuwdorp, Max

PY - 2019

Y1 - 2019

N2 - Purpose of Review: The aim of this review is to summarize the current data available on the metabolic effects of fecal microbiota transplantation (FMT) including obesity and glucose metabolism in humans. Recent Findings: Gut microbiota dysbiosis is a frequent characteristic observed in obesity and related metabolic diseases. Pieces of evidence mostly generated in mouse models suggest that rescuing this dysbiosis associates with improved metabolism. In humans, dietary or bariatric surgery interventions are often accompanied by complete or partial restoration of this dysbiosis together with weight reduction and metabolic amelioration. FMT is an interesting option to modify gut microbiota and has been associated with improved clinical outcomes, albeit only used in routine care for Clostridium difficile infection. However, there are only limited data on using FMT in the metabolic context. Summary: FMT from lean donors significantly improves insulin sensitivity in obese subjects with metabolic syndrome. However, there is a wide range of clinical responses. Interestingly in subjects with high microbial gene richness at baseline and when FMT donors that are metabolically compromised are used, no metabolic improvement is seen. Moreover, more studies evaluating the effect of FMT in patients with overt type 2 diabetes are warranted. Furthermore, interventions (in the receiver prior to FMT) aiming to enhance FMT response also need evaluation.

AB - Purpose of Review: The aim of this review is to summarize the current data available on the metabolic effects of fecal microbiota transplantation (FMT) including obesity and glucose metabolism in humans. Recent Findings: Gut microbiota dysbiosis is a frequent characteristic observed in obesity and related metabolic diseases. Pieces of evidence mostly generated in mouse models suggest that rescuing this dysbiosis associates with improved metabolism. In humans, dietary or bariatric surgery interventions are often accompanied by complete or partial restoration of this dysbiosis together with weight reduction and metabolic amelioration. FMT is an interesting option to modify gut microbiota and has been associated with improved clinical outcomes, albeit only used in routine care for Clostridium difficile infection. However, there are only limited data on using FMT in the metabolic context. Summary: FMT from lean donors significantly improves insulin sensitivity in obese subjects with metabolic syndrome. However, there is a wide range of clinical responses. Interestingly in subjects with high microbial gene richness at baseline and when FMT donors that are metabolically compromised are used, no metabolic improvement is seen. Moreover, more studies evaluating the effect of FMT in patients with overt type 2 diabetes are warranted. Furthermore, interventions (in the receiver prior to FMT) aiming to enhance FMT response also need evaluation.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85068063474&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31250122

U2 - 10.1007/s11892-019-1180-z

DO - 10.1007/s11892-019-1180-z

M3 - Review article

VL - 19

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 8

M1 - 51

ER -